Kornimate/medical-research-clean huggingface dataset:
effects of napping in sleep-restricted adolescents

Conditions: Sleep Deprivation; Sleep

Summary: to examine the neurobehavioural responses to two successive cycles of sleep restriction and recovery in adolescents, and to determine the benefits of napping on cognitive performance, alertness, and mood. 57 participants, aged 15 to 19 years old, were divided into nap and no-nap groups. both groups underwent two cycles of sleep restriction and recovery over 15 days. the nap group received an afternoon sleep opportunity lasting 1 hour.

57 participants (aged 15 to 19 years old) were grouped into nap and no nap groups. both groups took part in a 15-day protocol that started with 2 9-hour adaptation and baseline nights, followed by two successive cycles of sleep restriction (5-h time-in-bed \[tib\]; 01:00-06:00) and recovery (9-h tib; 23:00-08:00) intended to simulate the weekday sleep loss and weekend attempt to 'catch up' that are familiar to high school students. the nap group received a 1-hour nap opportunity at 14:00 following each sleep-restricted night, while participants in the no nap group watched a documentary. sleep was monitored with polysomnography on 9 selected nights. cognitive performance, subjective sleepiness, and mood were assessed 3 times daily (10:00, 15:45, and 20:00). all participants stayed in air-conditioned, twin-share bedrooms with en-suite bathrooms. bedroom windows were fitted with blackout panels to ensure participants were not woken up prematurely by sunlight. earplugs were also provided, and participants were allowed to adjust the temperature of their bedrooms to their personal comfort. 3 main meals were served each day, with snacks being provided for upon request. caffeinated drinks, unscheduled sleep, and strenuous physical activities were prohibited. outside of scheduled sleep, meal, and cognitive testing times, participants spent the majority of their free time in a common room that was illuminated by natural and artificial lighting. they were allowed to read, play non-physically exerting games, watch videos, and interact with research staff and other participants. participants were under constant supervision by the research staff.

Eligibility criteria:
inclusion criteria: * healthy * no sleep disorder * body mass index not greater than 30 exclusion criteria: * smoker * habitual short sleeper (time in bed during term time of less than 6 hours and no sign of sleep extension of greater than 1 hour on weekends) * consumption of more than 5 cups of caffeinated beverages a day * travelling across more than 2 time zones in the month prior to the study protocol * diagnosed with any psychiatric conditions

Keywords: nap sleep restriction recovery sleep cognitive performance subjective sleepiness mood neurobehavioural functions
uterine artery color doppler parameters after bilateral uterine artery ligation

Conditions: Postpartum Hemorrhage; Ligation; Color Doppler; Uterine Artery

Summary: the aim of this study is to assess uterine artery color doppler parameters after bilateral uterine artery ligation (bual) for postpartum hemorrhage.

obstetric haemorrhage is the main reason of maternal death in both countries with high and poor incomes. most of these deaths occurred within the first 24 hours following birth. placenta accrete, retained placenta, genital tract lacerations, uterine rupture, and coagulation abnormalities are established risk factors for postpartum hemorrhage. the management of idiopathic pulmonary hemosiderosis (iph) and postpartum hemorrhage relies on numerous considerations: type of delivery (vaginal or caesarean delivery), bleeding etiology (uterine atony, trauma, retained placenta) and hemodynamic stability. in the first stage, early identification, and treatment with uterotonics, suturing the lacerations, and fundal massage are crucial. when bleeding persist, even in the aggressive medical treatment, suitable surgical intervention should be performed. surgical therapy relies on the patient's desire to maintain fertility, the severity of the bleeding, and the surgeon's experience. historically, peripartum hysterectomy was the only available management to prevent postpartum hemorrhage but, in some instances, hysterectomy alone is insufficient to control the bleeding. also, the desire to preserve fertility have resulted in the development of other techniques, such as pelvic embolization and internal iliac artery ligation (iial)and bilateral uterine artery ligation (bual). bilateral uterine artery ligation (bual) is the most popular surgical procedure for quick management of postpartum hemorrhage. it may be performed alone or with conjugation with other postpartum hemorrhage methods in with success rate exceeds 90 %. recanalization is a natural process that may occur following vascular structure closure with a suture or radiological embolization.

Eligibility criteria:
inclusion criteria: * 70 women aged between 20 and 35 years old. * undergoing bilateral uterine artery ligation after postpartum hemorrhageafter cesarean section * resistant to medical treatment, and did not need to hysterectomy. exclusion criteria: * patients with male factor, tubal factor, and absence of lactation. * diabetes mellitus, hypertension, morbid obesity, autoimmune disease, or vascular disease in the history, smoking. * intrauterine growth restriction in previous pregnancies history, detection of a uterine anomaly or a medical condition, as well as administration of a hormonal treatment during the study. * uncontrolled bleeding is needed for a hysterectomy.
anti inflammatory lipid mediators in asthma lipid anti-inflammtory mediators in asthma

Conditions: Asthma; Obesity

Summary: the main purpose of this phase 2 double blind, placebo controlled crossover clinical study is to demonstrate the efficacy and safety of cxa-10 in obese adult asthmatics. obesity induces a chronic systemic inflammatory state characterized by impaired adipokine signaling, pro-inflammatory cytokine responses, inflammatory cell activation and enhanced generation of oxidative inflammatory mediators. this impacts the lung, increasing the severity of asthma and its exacerbations. this research will evaluate how a synthetic nitro-fatty acid (cxa-10, 10-nitro-octadec-9-enoic acid) suppresses the systemic and airway inflammation that contributes to the obese asthmatic phenotype. current data support the pleiotropic signaling actions of cxa-10 to induce adaptive signaling actions that beneficially modulate adipokine and cytokine expression and inhibit systemic and pulmonary inflammation. the investigators hypothesize that cxa-10 induced signaling responses will alleviate obesity-related airway hyperreactivity in obese adult asthmatics.


Eligibility criteria:
inclusion criteria: 1. adequate completion of informed consent process with written documentation. male and female patients, 18 to 65 years old. female subjects should be either post-menopausal or surgically sterile, or, if child-bearing potential (wocp) should agree to use an acceptable method of contraception, for the duration of the study, with a negative pregnancy test prior to entering the study. 2. bmi \>/= 30 3. diagnosis of asthma: based on previous physician diagnosis for \> 6 months, and baseline pre-bronchodilator (bd) fev1 between 50 and 95% predicted with either a 12% or greater bronchodilator response to 4 puffs of albuterol or pc20 methacholine (16 mg) if \<12% change post bd 4. regular treatment with inhaled corticosteroids (ics) (up to 1000 mcg/day fluticasone/equivalent), long acting beta agonists (laba), and/or long-acting muscarinic antagonists (lama), which can be combination medication for at least 3 months; on a stable dose for the 4 weeks prior to visit 0 exclusion criteria: 1. respiratory tract infection within the last 4 weeks 2. oral or systemic corticosteroid burst within the last 4 weeks 3. asthma-related hospitalization within the last 6 weeks 4. three or more asthma exacerbations requiring treatment with systemic corticosteroids in the past year consistent with severe asthma 5. asthma-related er visit within the previous 4 weeks 6. current smoking or have former smokers that quit within the previous 1 year, or 10 pack years
efficiency of placental drug melsmon® in correction of climacteric symptoms in premenopausal women

Conditions: Climacteric Syndrome

Summary: the placental drug melsmon® is effective for correction of insomnia and other climacteric symptoms in premenopausal women. decrease of mmi is shown both in groups with melsmon® and placebo, but it was more significant in patients who used melsmon®.

there were 40 women under the observation, with mild and moderate symptoms of climacteric syndrome with sleep disorders (for that the investigators evaluated modified kupperman index). all patients were randomized with the help of the envelope method with the allocation ratio of 1:1 (one-to-one). 20 women were prescribed placenta extract melsmon and 20 received placebo during 4 months.

Eligibility criteria:
inclusion criteria: * more than 40 years of age * irregular menstrual cycle * climacteric symptoms, including sleep disorders * follicule-stimulating hormone \>20 milli international units/ml - exclusion criteria: * non-controlled hypertension (more than 140 mm hg) * decompensated chronic diseases of the cardiovascular system, myocardial infarction, history of stroke * diabetes mellitus * kidney and hepatic dysfunction * cancer * breast fibroadenomas, adenomas and cysts * uterine fibroids with dominant nodule diameter ˃ 2 cm, * endometrial hyperplasia * individual drug idiosyncrasy * intake of any drugs for correction of climacteric symptoms and sleep disorders

Keywords: menopause, climacteric syndrome, insomnia, placental extract
chronic prostatitis/chronic pelvic pain syndrome patients

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Summary: chronic prostatitis/chronic pelvic pain syndrome (cpps) is a common health problem among men and can cause severe quality of life. the pathophysiology of cpps is still poorly understood and effective treatments are a challenging issue. this study aims to investigate the possible relationship between the presence of microorganisms in the prostatic fluid and symptom severity by presenting a retrospective analysis based on data from cpps patients.

this study is based on data from 112 cpps patients aged 20-60 years. various variables such as demographic information of the patients, international prostate symptom score (i-pss), which evaluates cpps symptoms, inflammatory and non-inflammatory symptoms of cpps, baseline scores of the international index of erectile function (iief), which evaluates erectile function, and the presence of microorganisms in the prostate fluid were analyzed retrospectively.

Eligibility criteria:
inclusion criteria: * patients who were diagnosed with chronic prostatitis/chronic pelvic pain syndrome and whose prostate fluid was taken with prostate massage and androflor testis were studied were included. exclusion criteria: * acute and/or chronic bacterial prostatitis, active history of genitourinary cancer, history of recent prostate surgery the diagnosis of neurological diseases affecting the bladder was determined
low-dose prednisone or methylprednisolone in treating patients with newly diagnosed acute graft-versus-host disease

Conditions: Graft Versus Host Disease; Recurrent Adult Acute Lymphoblastic Leukemia

Summary: this randomized phase iii trial is studying low-dose prednisone or methylprednisolone to see how well they work compared with standard-dose prednisone or methylprednisolone in treating patients with newly diagnosed acute graft-versus-host disease (gvhd). glucocorticoids, such as prednisone or methylprednisolone at a starting dose of 2 mg/kg/day are standard treatment for acute graft-versus-host disease caused by a donor stem cell transplant. it is not yet known whether low-dose glucocorticoids are more effective than standard-dose glucocorticoids in treating acute graft-versus-host-disease

objectives: i. to determine whether a lower starting dose of prednisone for treatment of newly diagnosed acute gvhd results in decreased prednisone exposure without compromising overall survival. ii. to estimate the magnitude of clinical benefit associated with the reduction in prednisone exposure. outline: patients are randomized to 1 of 2 treatment arms. arm i (low-dose; prednisone-equivalent dose at initiation of treatment of 0.5 mg/kg/day or 1.0 mg/kg/day; stratified according to initial symptom severity): patients receive low-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity. arm ii (standard-dose; prednisone-equivalent dose at initiation of treatment of 1.0 mg/kg/day or 2.0 mg/kg/day; stratified according to initial symptom severity): patients receive standard-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed up at 1 year and then annually thereafter.

Eligibility criteria:
inclusion criteria: * patients with newly diagnosed acute gvhd (\>= grade iia) for whom, in the judgment of the attending physician, initial treatment with systemic glucocorticoids is indicated * patient or guardian able and willing to provide informed consent exclusion criteria: * hallmarks of chronic gvhd * gvhd after donor lymphocyte infusion (dli) * patient unwilling to remain in seattle under the care of the fred hutchinson cancer research center (fhcrc)/seattle cancer care alliance (scca) through day 42 after the start of treatment for gvhd * uncontrolled infection or other underlying comorbidity (i.e. severe psychiatric illness) that precludes the use of "standard-dose" prednisone * recent diagnosis of recurrent or progressive malignancy that precludes the use of "standard-dose" prednisone * any prior systemic therapy for acute gvhd (patients may receive up to 2 doses of low-dose prednisone prior to randomization; low-dose prednisone is defined as 0.5 mg/kg/dose for patients who present with grade iia gvhd and 1 mg/kg/dose for those who present with grade iib-iv gvhd) * enrollment on blood and marrow transplant clinical trials network (bmt-ctn) trial 0802
hemodynamic response of anodal transcranial direct current stimulation over the cerebellar hemisphere in healthy subjects

Conditions: Stroke; Transcranial Direct Current Stimulation; Functional Near Infrared Spectroscopy

Summary: upper extremity motor impairment is one of the major sequelae of stroke, resulting in limitation of activities of daily livings. noninvasive neuromodulation is one of the therapies for motor recovery, which includes transcranial magnetic stimulation and transcranial direct current stimulation(tdcs). anodal tdcs increases excitability and cathodal tdcs decreases excitability of neurons. in systematic reviews, tdcs applied over primary motor cortex showed positive results on motor learning and improvements of hand fine motors. recently, there has been trials of tdcs over cerebellum, considering the connectivity of primary motor cortex and cerebellum in motor controls. however, the results of these trials are yet contradictory, and the study using the functional near infrared spectroscopy to prove the effects of tdcs over distant area is lacking. therefore, in this study, we used functional near infrared spectroscopy (fnirs) to observe the hemodynamic change of primary motor cortex when applying tdcs over cerebellum ascertain their connectivity. in this crossover design, participants are randomly allocated to "sham tdcs-washout period-anodal tdcs group" or "anodal tdcs- washout period- sham tdcs group". the recording of fnirs starts 3 minutes before the tdcs stimulation and continues throughout 20 minutes of stimulation, until 30 minutes after the stimulation cessation. after 7 days of washout period, second recording is done as the same protocol. outcome measures are the changes of concentration of deoxyhemoglobin \[deoxy-hb\] and oxyhemoglobin \[oxy-hb\].


Eligibility criteria:
inclusion criteria: * age: 19 years or older * no known brain disorders exclusion criteria: * uncontrolled or unstalbe medical condition * pregnant * scalp problem which interferese with tdcs * metals in the head (example: clip, coil), cochlear implants
russian labor migrant hiv prevention trial

Conditions: HIV

Summary: this study is a randomized outcome trial of a social network hiv prevention intervention for at-risk labor migrants who have arrived in st. petersburg, russia, to seek work. most come to st. petersburg from moldova, tajikistan, uzbekistan, ukraine, and other poor post-soviet republics. while living in russia, labor migrants are also living in a city and country with high hiv prevalence. many labor migrants have limited awareness of aids, and most are living in a location far from their spouses, family members, and others. for that reason, labor migrants are vulnerable to risk behavior for contracting hiv. this study hypothesizes that members of labor migrant social networks whose network leaders are trained to deliver hiv prevention messages will exhibit greater reductions in sexual risk behavior (unprotected intercourse with nonspousal partners) from baseline to 3- and 12-month followup assessments than will members of social networks whose members receive standard, individual hiv risk reduction counseling alone.


Eligibility criteria:
inclusion criteria: * being a labor migrant intending to temporarily work and reside in st. petersburg, russia, or being named as a member of the social network of a labor migrant; * being at least 16 years old (the age at which persons can be legal labor migrants and are also legally considered to be able to provide informed consent); * being able to complete written consent forms and questionnaire measures in russian, moldovan, tajik, or uzbek language * providing written informed consent exclusion criteria: * being younger than age 16; * not being able to complete written materials in the russian, moldovan, tajik, or uzbek language; * planning to reside in st. petersburg, russia, for less than four months; * having a severe mental or developmental disorder apparent by mental status during the study or consent explanation that, in the opinion of a trained interviewer, would preclude ability to understand informed consent or complete study measures
establishment of optimal transfusion threshold after major orthopedic surgery

Conditions: Anemia; Arthroplasty; Replacement; Hip

Summary: the purpose of this study is to determine whether a higher threshold for transfusion with red blood cells improves the postoperative ambulation.


Eligibility criteria:
inclusion criteria: * 18 years or older * patients undergoing replacement of hip arthroplasty * be legally competent * read and understand danish exclusion criteria: * present malignant disease * known heart disease with functionality equivalent to nyha ii or ccs ii or worse

Keywords: hemoglobin ambulation
executive dysfunction & suicide: an exploration of risk factors in traumatically brain injured veterans

Conditions: Traumatic Brain Injury (TBI); Suicidal Behavior

Summary: this is a study to learn more about traumatic brain injury (tbi) and suicidal behaviors. the purpose of this research is to find out more about the issues related to these conditions. this study seeks to explore the relationship between executive dysfunction and suicidal behavior in an outpatient population.


Eligibility criteria:
inclusion criteria: 1. diagnosis of traumatic brain injury, history of suicidal behavior. 2. age 18-74. 3. currently receiving care through the eastern colorado health care system (echcs) denver va tbi interdisciplinary team. exclusion criteria: 1. history of other significant neurological disease. 2. diagnosis of schizophrenia. 3. test of memory malingering (tomm) performance lower than 50%. 4. behavior which could be described as substance abuse in the 7 days prior to participation. 5. current guardianship or mention of recommendation for guardianship in medical chart within the past six months. 6. inability to read the informed consent document. 7. inability to adequately respond to questions regarding the informed consent procedure. 8. significant hearing impairment.
dose-escalating safety and preliminary efficacy of daxibotulinumtoxina for injection in cervical dystonia

Conditions: Torticollis (Spasmodic)

Summary: this is an open-label, dose-escalation study to assess the safety and preliminary efficacy of daxibotulinumtoxina in subjects with isolated cervical dystonia (cd).


Eligibility criteria:
inclusion criteria: * meets diagnostic criteria for isolated cervical dystonia * has moderate severity with a baseline toronto western spasmodic torticollis rating scale (twstrs) - total score of at least 20 and a twstrs-severity subscale score or at least 15 * has been using stable doses of focal dystonia medications for at least 3 months and willing to continue through end of study exclusion criteria: * cervical dystonia attributable to an underlying etiology, such as traumatic torticollis or tardive torticollis; predominant retrocollis or anterocollis cervical dystonia * significant dystonia in other body areas, or is currently being treated with botulinum toxin for dystonia in other areas than isolated cervical dystonia * neurological abnormalities other than cervical dystonia * history of severe dysphagia or aspiration, or current clinically significant swallowing disorder * previous neck surgery, phenol injection to the neck muscles, myotomy or denervation surgery in the neck/shoulder region, or intrathecal baclofen * marked limitation on passive range of motion that suggests contractures or other structural abnormality, e.g. cervical contractures or cervical spinal deformity * profound atrophy of cervical musculature * any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type a, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as lambert-eaton syndrome and myasthenia gravis * suboptimal efficacy response to any prior botulinum toxin type a product, when a previous treatment produced more optimal therapeutic response, as judged subjectively by the investigator * previous treatment with any botulinum toxin product for any condition within the 6 months prior to screening and during the study; presence of any blood coagulation disorder; or on anticoagulation treatment with international normalized ratio (inr) \> 3.5

Keywords: cervical dystonia spasmodic torticollis